
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid Ltd is a clinical-stage biopharmaceutical company focused on developing its proprietary PLEX-based drug delivery technology, with significant potential for addressing surgical site infections (SSI) through its primary candidate, D-PLEX100, which has shown promising efficacy in a Phase 3 clinical study. Recently, the company secured approximately $26.7 million in funding from a new agreement with shareholders, enabling it to efficiently plan a pre-New Drug Application (NDA) meeting with the FDA and paving the way for a potential NDA filing for D-PLEX100 in the first half of 2026. These developments enhance PolyPid's financial stability and the timely progression of its product candidates, creating a solid foundation for future growth and success in the biopharmaceutical market.
Bears say
PolyPid Ltd faces significant risks regarding the efficacy of its product candidates, as there is a possibility that the company's agents may not yield statistically significant results in clinical studies, which would greatly diminish the perceived value of these products. Additionally, even with successful clinical outcomes, the likelihood of failure to gain approval from regulatory agencies could further erode PolyPid’s value. Compounding these issues, the complexity surrounding patent procedures raises concerns about potential revenue erosion starting in 2036, adding to the company's uncertain financial outlook.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares